AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 17.7361
- Book/Share 13.2681
- PB 10.6992
- Debt/Equity 0.7625
- CurrentRatio 0.8974
- ROIC 0.1098
- MktCap 439149158932.0
- FreeCF/Share 2.9477
- PFCF 48.0575
- PE 56.4956
- Debt/Assets 0.2945
- DivYield 0.0217
- ROE 0.1918
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
Trumps 200% tariffs. Here's what it means for UK pharma investors
Published: July 10, 2025 by: Proactive Investors
Sentiment: Negative
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
Read More
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN) should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
Read More
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
Read More
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Read More
Why AstraZeneca Stock Got Thumped on Thursday
Published: July 03, 2025 by: The Motley Fool
Sentiment: Positive
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
Read More
Report: Summit in talks for $15 billion partnership with AstraZeneca
Published: July 03, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Read More
Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports
Published: July 03, 2025 by: Reuters
Sentiment: Positive
Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca , Bloomberg News reported on Thursday, citing people familiar with the matter.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Are these the UK's top income stocks? One leading bank thinks so
Published: July 02, 2025 by: Proactive Investors
Sentiment: Neutral
Reliable income stocks are a staple of a balanced portfolio. But according to research from UBS, the UK has only a handful that warrant close attention.
Read More
AstraZeneca shares pop on news CEO wants to move base to US
Published: July 01, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) shares spiked higher on Tuesday afternoon on reports that the boss of the UK pharmaceutical giant wants to move the company to the US. CEO Pascal Soriot wants to the FTSE 100's largest company to leave the UK due to his frustration with restrictions on medicines and pricing under the NHS, according to a report in The Times.
Read More
AstraZeneca CEO eyes US market listing, The Times reports
Published: July 01, 2025 by: Reuters
Sentiment: Positive
AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United States, The Times reported on Tuesday, citing multiple sources.
Read More
AstraZeneca: Navigating Challenges Across Geographies Well
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Negative
AstraZeneca's price performance YTD exceeds the healthcare sector and broader markets, indicating investors are assuaged regarding concerns across geographies. The company has offered greater clarity on why its under investigation in China, and so far there's reason to believe matters are under control. US tariffs are unlikely to affect its financials significantly in 2025 either, with the company assuring that only a minority of treatments are imported into the market.
Read More
Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
Read More
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AstraZeneca and GSK fall after Trump renews pharma tariff threat
Published: June 18, 2025 by: Proactive Investors
Sentiment: Negative
Shares in AstraZeneca PLC (LSE:AZN), the largest company on the FTSE 100 index, and fellow blue chip GSK PLC (LSE:GSK, NYSE:GSK) were down 1.4% and 1.9% respectively on renewed worries about US drug tariffs. The pharmaceutical pair were a large drag on the London index after US President Donald Trump said tariffs on imported drugs could be imposed “very soon”, echoing comments from two months ago.
Read More
Is Trump targeting the NHS in trade negotiations? This reports says it is
Published: June 16, 2025 by: Proactive Investors
Sentiment: Negative
Britain could face higher drug costs as part of a deal to stave off future tariffs from Donald Trump, according to a report in the Daily Telegraph. Documents released after a recent trade agreement show the NHS is expected to review its approach to drug pricing in response to US demands.
Read More
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes
Published: June 12, 2025 by: Proactive Investors
Sentiment: Positive
UBS has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, offering potential upside of just over 30% from the current share price of 10,907p. The focus is on two high-profile drug candidates with contrasting outlooks.
Read More
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.
Read More
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
Read More
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, and more.
Read More
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Published: June 02, 2025 by: Investors Business Daily
Sentiment: Neutral
Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.
Read More
Danaher Partners With AstraZeneca to Support Precision Medicine
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Read More
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
Read More
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
Read More
Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.
Read More
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300